清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Potential Toxic Effects of Olanzapine on Metabolic Parameters in de Novo Paranoid Schizophrenic Patients. The Role of Adjunctive Aripeprazole: Clinical and Experimental Study

作者
Hisham Mohammed Al-sayed,Wafaa Ibrahim Soliman
出处
期刊:Occupational diseases and environmental medicine [Scientific Research Publishing, Inc.]
卷期号:07 (03): 91-113
标识
DOI:10.4236/odem.2019.73008
摘要

Background: Approximately 75% of all deaths in people with schizophrenia are caused by physical illness with cardiovascular disease [CVD] being the commonest cause of death. Factors predisposing people with schizophrenia to CVD include antipsychotic medication. Aim of Work: The aim of this study was to detect metabolic syndrome and its components in de novo paranoid schizophrenics on olanzapine therapy and the metabolic benefits of addition of aripeprazole, clinically and experimentally. Methodology: 1) Clinical study: 200 Outpatients suffered from de novo paranoid schizophrenia according to 10th International Classification of Psychiatric Disorders, Research Criteria [ICD10 RC] were included in the study. None of them had any component of metabolic syndrome. They were maintained on olanzapine [10 - 20 mg]. Patients were assessed clinically, psychometrically using Scale for the Assessment of Negative [SANS] and Positive [SAPS] Symptoms and metabolically at base line and after 6 months. Patients who had metabolic syndrome after 6 month of starting olanzapine therapy, were randomly divided into two groups according to added regime to maintained olanzapine: Group 1: olanzapine [10 mg/day] + placebo [empty hard gelatin capsule]. Group II: olanzapine [10 mg/day] + aripeprazole [10 mg/day]. 2) Experimental study: 40 male albino rats were randomly equally divided into 4 groups: Group 1 [control group]: received a standard diet, Group II [olanzapine treated]: received olanzapine at a dose of 0.5 mg/kg/day, Group III [aripiprazole treatd]: received aripiprazole at a dose of 2 mg/kg/day, Group IV [combined olanzapine and aripiprazole treated]: received olanzapine at a dose of 0.5 mg/kg/day combined with aripiprazole at a dose of 2 mg/kg/day orally. The duration of the study was 16 weeks. All treated rat groups were assessed for metabolic parameters, liver enzymes and histopathology. Results: Clinically, after the 6 months of olanzapine treatment [mean dose 12.75 mg], there was significant increase [p < 0.001] in weight, body mass index, triglyceride, total cholesterol, and fasting blood glucose level compared to base line level of these parameters (Table 1). 32 patients [16%] suffered from metabolic syndrome after 6 months of olanzapine therapy. After 3 months of aripeprazole, [10 mg/day], addition to maintained olanzapine therapy to patients suffered from metabolic syndrome, there was significant [p < 0.001] improvement in tested parameters (Table 2). Experimentally, the rats in group II [olanzapine treated rats] had significantly higher body weight [p = 0.002], liver weight [p < 0.001], metabolic parameters [p < 0.001] and liver enzymes [p < 0.001] than controls. Group 1v [combined olanzapine and aripeprazole treated rats] had significant decrease in metabolic parameters and liver enzymes in comparison to olanzapine treated rats (Table 3). Histopathologically, liver fat cells were significantly [p < 0.001] present in the olanzapine-only [8 rats] treatment group compared to group 1v [3 rats] and group 11 [zero]. Liver fat cells were higher in number and larger in size in group 1 compared to group 1v and group 1. Conclusion and Recommendation: Olanzapine treatment was found to be associated with risk factors of metabolic syndrome clinically and experimentally and its hepatic manifestation of non-alcoholic fatty liver disease in wister rats. Improvements were observed clinically and experimentally in metabolic measures, liver enzymes and liver histopathology by addition of aripeprazole. Patients on olanzapine therapy must be followed regularly regarding metabolic parameters, hepatic, cardiac and cerebrovascular morbidity, with urgent interference with early manifestations. It is recommended to check liver enzymes regularly for those patients kept on atypical antipsychotic drug [olanzapine].

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
wyl完成签到 ,获得积分10
2秒前
莫忘初心完成签到,获得积分10
3秒前
kaka完成签到,获得积分10
3秒前
129完成签到,获得积分10
3秒前
如歌完成签到,获得积分10
5秒前
205完成签到,获得积分10
8秒前
卡卡完成签到,获得积分10
8秒前
聪明的羿完成签到,获得积分10
8秒前
8秒前
顺心凝阳完成签到,获得积分10
9秒前
shiluodeqiou完成签到,获得积分10
10秒前
白昼完成签到,获得积分10
11秒前
ZHZ完成签到,获得积分10
11秒前
321987杰完成签到 ,获得积分10
13秒前
内向的镜子完成签到,获得积分10
13秒前
MaidLingYan完成签到,获得积分10
13秒前
huan完成签到,获得积分10
16秒前
ssnwlp123完成签到,获得积分10
16秒前
BlueLe完成签到,获得积分10
17秒前
Zilaap完成签到,获得积分10
18秒前
CaptainMus完成签到,获得积分10
19秒前
端庄的如松完成签到,获得积分10
19秒前
皮卡皮卡皮卡丘完成签到,获得积分10
20秒前
Maestro_S的应助被科研通管家采纳,获得10
21秒前
null的应助被科研通管家采纳,获得10
22秒前
花开富贵完成签到,获得积分10
23秒前
luyu完成签到,获得积分10
23秒前
mayberichard完成签到,获得积分10
23秒前
热情善斓完成签到,获得积分10
24秒前
dianeil发布了新的文献求助10
24秒前
hh完成签到,获得积分10
26秒前
昊儿虫完成签到,获得积分10
26秒前
宝哥完成签到,获得积分10
26秒前
顺心雁开完成签到,获得积分10
29秒前
Cling5899完成签到,获得积分10
30秒前
bao完成签到,获得积分10
31秒前
小冯完成签到,获得积分10
35秒前
fomo完成签到,获得积分0
36秒前
坦率钢笔完成签到,获得积分10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834410
捐赠科研通 7782895
什么是DOI,文献DOI怎么找? 3434567
关于科研通互助平台的介绍 2558844
邀请新用户注册赠送积分活动 2481280